Skip to content

Biohaven BHVN Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Biohaven (BHVN) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $3K in Q1 2026.
How has Biohaven's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
Biohaven's debt securities, available-for-sale, accumulated gross unrealized loss, before tax decreased by 90.3% year-over-year, from $31K to $3K.
What is the long-term trend for Biohaven's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Over 3 years (2022 to 2025), Biohaven's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -100.0% compound annual growth rate (CAGR), from $196K to $0.